---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-014570"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:55:21.426000+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics CEO resigns; Q1 net loss widens to $11.8M, revenue $2.9M

## Summary
- CEO Richard W. Pascoe resigns effective June 1, 2023; Chief Development Officer Christal Mickle appointed interim CEO.
- Q1 net loss of $11.8M ($0.34 per share) vs $1.9M loss a year ago; revenue fell to $2.9M from $4.0M.
- Cash and investments $95.3M; expects operating runway into 2026, funding arimoclomol NDA resubmission and KP1077 program.
- Arimoclomol NDA resubmission for NPC anticipated as early as Q3 2023; KP1077 Phase 2 IH interim data expected Q3 2023.
- Share repurchases of 665,739 shares for ~$3.4M during Q1; $39.1M remaining under program.

## SEC filing metadata
- accession: 0001437749-23-014570
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/kmph20230112_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-014570
- JSON: https://secwatch.observer/filing/0001437749-23-014570.json
- Plain text: https://secwatch.observer/filing/0001437749-23-014570.txt

## Key facts
- Earnings Releases
  ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: EPS ($0.34) per basic and diluted share.
  - Period: first quarter ended March 31, 2023
  - EPS: ($0.34) per basic and diluted share
  - Result: reported results
  source text: Net revenue for Q1 2023 was $2.9 million compared to Q1 2022 net revenue of $4.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm
- Earnings Releases
  ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: EPS ($0.34) per basic and diluted share.
  - Period: first quarter ended March 31, 2023
  - EPS: ($0.34) per basic and diluted share
  - Result: reported results
  source text: Net loss attributable to common stockholders for Q1 2023 was ($11.8) million, or ($0.34) per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm
- Executive change
  Richard W. Pascoe resigned as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: As previously reported, Richard W. Pascoe resigned as Zevra’s Chief Executive Officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm
- Executive change
  Christal M. M. Mickle was appointed as interim President and Chief Executive Officer at ZEVRA THERAPEUTICS, INC..
  - Action: appointed
  - Role: interim President and Chief Executive Officer
  source text: On May 13, 2023, Zevra’s Board of Directors (the “Board”) appointed Christal M.M. Mickle, Zevra’s Chief Development Officer, as Zevra’s interim President and Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.